Study of efficacy of ischemia reversal program (IRP) in ischemic heart disease (IHD) patients with VO2max and Duke’s treadmill score

Rohit Sane, Varada Sugwekar, Aarti Nadapude, Archana Hande, Gayatri Depe, Rahul Mandole


Background: Number of people dying from IHD has increased from 0.61 million in 1990 to 1.13 million in 2010, which is a disturbing fact. According to report by World Health Organization, India would be spending a whopping 237 billion US dollars, owing to direct spending on health care and indirectly due to loss of productivity due to IHD. Ischemia Reversal Program (IRP) is a combination of Panchakarma and allied therapy. This study was conducted to evaluate the effect of IRP on VO2max, Duke’s treadmill score, systolic blood pressure (SBP), diastolic blood pressure (DBP), and dependency on conventional therapy in IHD patients.

Methods: This observational study was conducted in January 2017, wherein the data of IHD patients (inducible ischemia on stress testing) who attended out-patient departments (OPDs) at Madhavbaug clinics in Maharashtra, India were identified. Data of patients who were administered IRP (60-75 minutes) with minimum 7 sittings over 90 days (±15 days) were considered. Variables were compared between day 1 and day 90 of the IRP.

Results: Out of 38 enrolled patients, 25 were males while 13 females. There was significant improvement in Duke’s score with  subjects at moderate (50%) and high (31.6%) risk at baseline were significantly decreased to low (52.6%) and moderate (47.4%) after the 90th day of therapy.  IRP also showed significant improvement in VO2max by 9.11 (from 20.29±6.72 to 29.40±6.71; p<0.001), SBP by 5.78 (from 128.78±17.40 to 123±12.23, p<0.03), DBP by 4.76 (from 80.53±8.10 to 75.76±6.85, p<0.005). Dependency on concomitant medicines was reduced.

Conclusions: IRP was effective in IHD; it had dual benefits, i.e. anti-ischemic effect, as well as reducing the dependency on allopathic medicines.


Alternative medicine, Blood pressure, Diastolic, Ischemia reversal program, IRP, Ischemic heart disease, IHD, Panchakarma

Full Text:



World Health Organization. Global Status Report on Non-Communicable Diseases 2014. Geneva, Switzerland: World Health Organization; 2014.

Fuster V, Kelly B. Board for global health. Promoting cardiovascular health in developing world: a critical challenge to achieve global health. Washington, DC: Institutes of Medicine; 2010.

Gaziano T, Gaziano J. Epidemiology of cardiovascular disease. In: Harrison’s Principles of Internal Medicine. 19th ed. New York, NY: McGraw Hill;2016:266.e1e5.

Gupta R, Guptha S, Sharma KK, Gupta A, Deedwania P. Regional variations in cardiovascular risk factors in India: India heart watch. World J Cardiol. 2012 Apr 26;4(4):112

Forouzanfar MH, Moran AE, Flaxman AD, Roth G, Mensah GA, Ezzati M, et al. Assessing the global burden of ischemic heart disease, part 2: analytic methods and estimates of the global epidemiology of ischemic heart disease in 2010. Global Heart. 2012;7:331e42.

Global Burden of Diseases 2013 Mortality and Causes of Death Collaborators. Global, regional, and national levels of age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117e71.

World Health Organization. Global atlas on cardiovascular disease prevention and control. Geneva, Switzerland; 2011. Available from:

GBD Profile: India. Institute of Health Metrics and Evaluation. Available from: Accessed April 30, 2014.

Al-Lawati S. A report on patient non-adherence in Ireland. Dublin:Pfizer;2014.

O’Connor P. Improving medication adherence: challenges for physicians, payers, and policy makers. Arch Intern Med. 2006;166:1802-4.

Kolandaivelu K, Leiden BB, O'gara PT, Bhatt DL. Non-adherence to cardiovascular medications. European heart journal. 2014 Sep 29;35(46):3267-76.

Gupta R, Mohan I, Narula J. Trends in coronary heart disease epidemiology in India. Annals of global health. 2016 Mar 1;82(2):307-15.

Al-Nimer MS. Evaluation of anti-ischemic therapy in coronary artery disease: a review. In Coronary Artery Diseases 2012. InTech. Available from: disease-a-review.

Gui QF, Xu ZR, Xu KY, Yang YM. The efficacy of ginseng-related therapies in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Medicine. 2016 Feb;95(6).

Huang H, Lai S, Wan Q, Qi W, Liu J. Astragaloside IV protects cardiomyocytes from anoxia/reoxygenation injury by upregulating the expression of Hes1 protein. Canadian J physiology and pharmacol. 2015 Dec 16;94(5):542-53.

Fleming J, Kris-Etherton P. The evidence for a-linolenic acid and cardiovascular disease benefits: comparisons with eicosapentaenoic acid and docosahexaenoic acid. Adv Nutr. 2014;5:863S-76S.

Choudhary K, Sharma P, Sharma V. Hypertension and its management through Panchakarma, J of Ayurveda and Hol Med. 2015;3(3):28-31.

Uebaba K, Xu FH, Ogawa H, Tatsuse T, Wang BH, Hisajima T, Venkatraman S. Psychoneuroimmunologic effects of Ayurvedic oil-dripping treatment. J alternative complementary Med. 2008 Dec 1;14(10):1189-98.

Taghadosi M, Arani Z, Gilani H. Quality of life in patients with ischemic heart disease. J Nursing Midwifery Sci. 2014:1(1):19-26

Sane R, Aklujkar A, Patil A, Mandole R. Effect of heart failure reversal treatment as add-on therapy in patients with chronic heart failure: A randomized, open-label study. Indian Heart J. 2017;69(3):299-304.

Liperoti R, Vetrano DL, Bernabei R, Onder G. Herbal medications in cardiovascular medicine. J American Coll Cardiol. 2017 Feb 27;69(9):1188-99.

Zhang S, Li H, Yang S. Tribulosin protects rat hearts from ischemia/reperfusion injury. Acta Pharmacologica Sinica. 2010;31(6):671-78.

Bhattacharjee S, Banerjee N, Chatterjee S, Santra T, Chatterjee S, Chatterjee A, et al. Role of turmeric in management of different non-communicable diseases. World J Pharm Pharm Sci. 2017 May 20;6:1767-78.

Gopa B, Bhatt J, Hemavathi K. A comparative clinical study of hypolipidemic efficacy of Amla (Emblica officinalis) with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitor simvastatin. Indian J Pharmacology. 2012;44(2):238-42.

Lairikyengbam S, Davies A. Interpreting exercise treadmill tests needs scoring system. BMJ. 2002;325(7361):443.

Chhatre S, Nesari T, Somani G, Kanchan D, Sathaye S. Phytopharmacological overview of Tribulus terrestris. Pharmacognosy reviews. 2014 Jan;8(15):45.

Lele SS, Macfarlane D, Morrison S, Thomson H, Khafagi F, Frenneaux M. Determinants of exercise capacity in patients with coronary artery disease and mild to moderate systolic dysfunction: Role of heart rate and diastolic filling abnormalities. European heart J. 1996 Feb 1;17(2):204-12.

César MD, Montesano FT, Diniz RV, Almeida DR, Tebexreni AS, Barros TL. Cardiopulmonary responses to exercise in patients of different age group with congestive heart failure. Arquivos brasileiros de cardiologia. 2006 Jan;86(1):14-8.